Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 1/2020

17.10.2019 | 2019 SSAT Plenary Presentation

The Immune Microenvironment Impacts Survival in Western Patients with Gastric Adenocarcinoma

verfasst von: Abhineet Uppal, Ahmed Dehal, Shu-Ching Chang, Dany Barrak, Yalda Naeini, John R. Jalas, Anton J. Bilchik

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Expression of CD3+ T cells, CD8+ cytotoxic T cells, CD45RO+ memory T cells, and FOXP3+ regulatory T cells at the invasive margin (IM) and tumor center (TC) has correlated with survival in gastric adenocarcinoma (GA) patients from East Asia, independent of anatomic staging. The reason for improved survival in East Asians compared with Western patients is a subject of debate. This study examined the immune profiles of a cohort of Western patients with GA, and their association with overall survival (OS).

Methods

Immunohistochemistry (IHC) using antibodies to CD3, CD4, CD8, CD45RO, and FOXP3 was performed on a randomly selected resected GA specimens from 88 Western patients. Cutoffs for high or low expression of each marker were determined with maximally selected rank statistics, and multivariable Cox proportional-hazards models constructed to evaluate the relationship between OS and expression of each marker at the IM and TC.

Results

Immune cell density was independent of anatomic staging. High expression of CD3, CD4, CD8, and CD45RO at the IM along with CD4 and FOXP3 at the TC were associated with improved OS. A combined marker of CD3, CD8, CD45RO, and FOXP3 associated with OS in East Asian GA was also validated.

Discussion

This is the first report in US patients to demonstrate that high expression of multiple subsets of T lymphocytes in GA is associated with better OS independent of clinical factors and anatomic stage. Further evaluation of immune-modulating mechanisms may explain survival differences between Western and Eastern patients and provide opportunity for novel treatments.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Kweon S.-S.: Updates on Cancer Epidemiology in Korea, 2018. Chonnam Medical Journal. 2018; 54:90–100.CrossRef Kweon S.-S.: Updates on Cancer Epidemiology in Korea, 2018. Chonnam Medical Journal. 2018; 54:90–100.CrossRef
3.
Zurück zum Zitat Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Niksic M., et al.: Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391:1023–1075.CrossRef Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Niksic M., et al.: Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391:1023–1075.CrossRef
4.
Zurück zum Zitat Jun J.K., Choi K.S., Lee H.Y., Suh M., Park B., Song S.H., et al.: Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017; 152:1319–1328 e1317.CrossRef Jun J.K., Choi K.S., Lee H.Y., Suh M., Park B., Song S.H., et al.: Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017; 152:1319–1328 e1317.CrossRef
5.
Zurück zum Zitat Lee S., Jun J.K., Suh M., Park B., Noh D.K., Jung K.W., et al.: Gastric cancer screening uptake trends in Korea: results for the National Cancer Screening Program from 2002 to 2011: a prospective cross-sectional study. Medicine (Baltimore). 2015; 94:e533.CrossRef Lee S., Jun J.K., Suh M., Park B., Noh D.K., Jung K.W., et al.: Gastric cancer screening uptake trends in Korea: results for the National Cancer Screening Program from 2002 to 2011: a prospective cross-sectional study. Medicine (Baltimore). 2015; 94:e533.CrossRef
6.
Zurück zum Zitat Saumoy M., Schneider Y., Shen N., Kahaleh M., Sharaiha R.Z., Shah S.C.: Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity. Gastroenterology. 2018; 155:648–660.CrossRef Saumoy M., Schneider Y., Shen N., Kahaleh M., Sharaiha R.Z., Shah S.C.: Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity. Gastroenterology. 2018; 155:648–660.CrossRef
7.
Zurück zum Zitat Jiang Y., Zhang Q., Hu Y., Li T., Yu J., Zhao L., et al.: ImmunoScore Signature: a Prognostic and Predictive Tool in Gastric Cancer. Ann Surg. 2018; 267:504–513.CrossRef Jiang Y., Zhang Q., Hu Y., Li T., Yu J., Zhao L., et al.: ImmunoScore Signature: a Prognostic and Predictive Tool in Gastric Cancer. Ann Surg. 2018; 267:504–513.CrossRef
8.
Zurück zum Zitat Lee J.S., Won H.S., Sun S., Hong J.H., Ko Y.H.: Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97:e11769.CrossRef Lee J.S., Won H.S., Sun S., Hong J.H., Ko Y.H.: Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97:e11769.CrossRef
9.
Zurück zum Zitat Amin M.B., American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. Eight edition/editor-in-chief, Mahul B. Amin, MD, FCAP; editors, Stephen B. Edge, MD, FACS and 16 others; Donna M. Gress, RHIT, CTR-Technical editor; Laura R. Meyer, CAPM-Managing editor. ed. Chicago IL: American Joint Committee on Cancer, Springer; 2017. Amin M.B., American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. Eight edition/editor-in-chief, Mahul B. Amin, MD, FCAP; editors, Stephen B. Edge, MD, FACS and 16 others; Donna M. Gress, RHIT, CTR-Technical editor; Laura R. Meyer, CAPM-Managing editor. ed. Chicago IL: American Joint Committee on Cancer, Springer; 2017.
10.
Zurück zum Zitat Zeng D., Zhou R., Yu Y., Luo Y., Zhang J., Sun H., et al.: Gene expression profiles for a prognostic immunoscore in gastric cancer. British Journal of Surgery. 2018; 105:1338–1348.CrossRef Zeng D., Zhou R., Yu Y., Luo Y., Zhang J., Sun H., et al.: Gene expression profiles for a prognostic immunoscore in gastric cancer. British Journal of Surgery. 2018; 105:1338–1348.CrossRef
11.
Zurück zum Zitat Pages F., Mlecnik B., Marliot F., Bindea G., Ou F.S., Bifulco C., et al.: International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391:2128–2139.CrossRef Pages F., Mlecnik B., Marliot F., Bindea G., Ou F.S., Bifulco C., et al.: International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391:2128–2139.CrossRef
12.
Zurück zum Zitat Schuler T, Blankenstein T.: Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol. 2003; 170:4427–4431CrossRef Schuler T, Blankenstein T.: Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol. 2003; 170:4427–4431CrossRef
13.
Zurück zum Zitat Kang B.W., Kim J.G., Lee I.H., Bae H.I., Seo A.N.: Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. World J Gastrointest Oncol. 2017; 9:293–299.CrossRef Kang B.W., Kim J.G., Lee I.H., Bae H.I., Seo A.N.: Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. World J Gastrointest Oncol. 2017; 9:293–299.CrossRef
14.
Zurück zum Zitat Zhou S., Shen Z., Wang Y., Ma H., Xu S., Qin J., et al.: CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One. 2013; 8:e74430.CrossRef Zhou S., Shen Z., Wang Y., Ma H., Xu S., Qin J., et al.: CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One. 2013; 8:e74430.CrossRef
15.
Zurück zum Zitat Wakatsuki K., Sho M., Yamato I., Takayama T., Matsumoto S., Tanaka T., et al.: Clinical impact of tumor-infiltrating CD45RO(+) memory T cells on human gastric cancer. Oncol Rep. 2013; 29:1756–1762.CrossRef Wakatsuki K., Sho M., Yamato I., Takayama T., Matsumoto S., Tanaka T., et al.: Clinical impact of tumor-infiltrating CD45RO(+) memory T cells on human gastric cancer. Oncol Rep. 2013; 29:1756–1762.CrossRef
16.
Zurück zum Zitat Lee H.E., Chae S.W., Lee Y.J., Kim M.A., Lee H.S., Lee B.L., et al.: Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008; 99:1704–1711.CrossRef Lee H.E., Chae S.W., Lee Y.J., Kim M.A., Lee H.S., Lee B.L., et al.: Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008; 99:1704–1711.CrossRef
17.
Zurück zum Zitat Perrone G., Ruffini P.A., Catalano V., Spino C., Santini D., Muretto P., et al.: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 2008; 44:1875–1882.CrossRef Perrone G., Ruffini P.A., Catalano V., Spino C., Santini D., Muretto P., et al.: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 2008; 44:1875–1882.CrossRef
18.
Zurück zum Zitat Zheng X., Song X., Shao Y., Xu B., Chen L., Zhou Q., et al.: Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. Oncotarget. 2017; 8:57386–57398.PubMedPubMedCentral Zheng X., Song X., Shao Y., Xu B., Chen L., Zhou Q., et al.: Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. Oncotarget. 2017; 8:57386–57398.PubMedPubMedCentral
19.
Zurück zum Zitat Yuan L., Xu B., Yuan P., Zhou J., Qin P., Han L., et al.: Tumor-infiltrating CD4+ T cells in patients with gastric cancer. Cancer Cell International. 2017; 17:114.CrossRef Yuan L., Xu B., Yuan P., Zhou J., Qin P., Han L., et al.: Tumor-infiltrating CD4+ T cells in patients with gastric cancer. Cancer Cell International. 2017; 17:114.CrossRef
20.
Zurück zum Zitat Liu K., Yang K., Wu B., Chen H., Chen X., Chen X., et al.: Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (Baltimore). 2015; 94:e1631.CrossRef Liu K., Yang K., Wu B., Chen H., Chen X., Chen X., et al.: Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (Baltimore). 2015; 94:e1631.CrossRef
21.
Zurück zum Zitat Breart B, Lemaitre F, Celli S, Bousso P.: Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest. 2008; 118:1390–1397.CrossRef Breart B, Lemaitre F, Celli S, Bousso P.: Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest. 2008; 118:1390–1397.CrossRef
22.
Zurück zum Zitat Ostroumov D., Fekete-Drimusz N., Saborowski M., Kühnel F., Woller N.: CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018; 75:689–713.CrossRef Ostroumov D., Fekete-Drimusz N., Saborowski M., Kühnel F., Woller N.: CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018; 75:689–713.CrossRef
23.
Zurück zum Zitat Szylberg L., Karbownik D., Marszalek A.: The Role of FOXP3 in Human Cancers. Anticancer Res. 2016; 36:3789–3794.PubMed Szylberg L., Karbownik D., Marszalek A.: The Role of FOXP3 in Human Cancers. Anticancer Res. 2016; 36:3789–3794.PubMed
24.
Zurück zum Zitat Ma G.F., Chen S.Y., Sun Z.R., Miao Q., Liu Y.M., Zeng X.Q., et al.: FOXP3 inhibits proliferation and induces apoptosis of gastric cancer cells by activating the apoptotic signaling pathway. Biochem Biophys Res Commun. 2013; 430:804–809.CrossRef Ma G.F., Chen S.Y., Sun Z.R., Miao Q., Liu Y.M., Zeng X.Q., et al.: FOXP3 inhibits proliferation and induces apoptosis of gastric cancer cells by activating the apoptotic signaling pathway. Biochem Biophys Res Commun. 2013; 430:804–809.CrossRef
25.
Zurück zum Zitat Hao Q., Zhang C., Gao Y., Wang S., Li J., Xue X., Li W., Zhang W., Zhang Y.: FOXP3 inhibits NF-kB activity and hence COX2 expression in gastric cancer cells. Cell Signal. 2014; 26:564–569.CrossRef Hao Q., Zhang C., Gao Y., Wang S., Li J., Xue X., Li W., Zhang W., Zhang Y.: FOXP3 inhibits NF-kB activity and hence COX2 expression in gastric cancer cells. Cell Signal. 2014; 26:564–569.CrossRef
26.
Zurück zum Zitat Choi H.S., Ha S.Y., Kim H.M., Ahn S.M., Kang M.S., Kim K.M., et al.: The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget. 2016; 7:7940–7951.PubMedPubMedCentral Choi H.S., Ha S.Y., Kim H.M., Ahn S.M., Kang M.S., Kim K.M., et al.: The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget. 2016; 7:7940–7951.PubMedPubMedCentral
27.
Zurück zum Zitat Beckhove P., Feuerer M., Dolenc M., Schuetz F., Choi C., Sommerfeldt N., et al: Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest. 2004; 114:67–76.CrossRef Beckhove P., Feuerer M., Dolenc M., Schuetz F., Choi C., Sommerfeldt N., et al: Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest. 2004; 114:67–76.CrossRef
28.
Zurück zum Zitat Coutzac C., Pernotab S., Chaput N., Zaanan A. Immunotherapy in advanced gastric cancer, is it the future? Crit Rev Oncol Hematol. 2019;133:25–32.CrossRef Coutzac C., Pernotab S., Chaput N., Zaanan A. Immunotherapy in advanced gastric cancer, is it the future? Crit Rev Oncol Hematol. 2019;133:25–32.CrossRef
29.
Zurück zum Zitat Strong V.E., Song K.Y., Park C.H., Jacks L.M., Gonen M., Shah M., et al.: Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251:640–6.CrossRef Strong V.E., Song K.Y., Park C.H., Jacks L.M., Gonen M., Shah M., et al.: Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251:640–6.CrossRef
30.
Zurück zum Zitat Wang J., Sun Y., Bertagnolli M.M. Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database. Ann Surg Oncol. 2015;22:2965–71.CrossRef Wang J., Sun Y., Bertagnolli M.M. Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database. Ann Surg Oncol. 2015;22:2965–71.CrossRef
31.
Zurück zum Zitat Strong V.E., Wu A.W., Selby L.V., Gonen M., Hsu M., Song K.Y., et al.: Differences in gastric cancer survival between the U.S. and China. J Surg Oncol. 2015;112:31–7.CrossRef Strong V.E., Wu A.W., Selby L.V., Gonen M., Hsu M., Song K.Y., et al.: Differences in gastric cancer survival between the U.S. and China. J Surg Oncol. 2015;112:31–7.CrossRef
32.
Zurück zum Zitat Lin S.J., Gagnon-Bartsch J.A., Tan I.B., Earle S., Ruff L., Pettinger K., et al.: Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.Gut. 2015;64:1721–31.CrossRef Lin S.J., Gagnon-Bartsch J.A., Tan I.B., Earle S., Ruff L., Pettinger K., et al.: Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.Gut. 2015;64:1721–31.CrossRef
Metadaten
Titel
The Immune Microenvironment Impacts Survival in Western Patients with Gastric Adenocarcinoma
verfasst von
Abhineet Uppal
Ahmed Dehal
Shu-Ching Chang
Dany Barrak
Yalda Naeini
John R. Jalas
Anton J. Bilchik
Publikationsdatum
17.10.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 1/2020
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04403-w

Weitere Artikel der Ausgabe 1/2020

Journal of Gastrointestinal Surgery 1/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.